Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie is entering a collaboration and license option deal ...
Exsilio Therapeutics launched on Wednesday with an $82 million series A fundraising round co-led by Novartis Venture Fund and Delos Capital. The company’s interim CEO, Tal Zaks, says that while ...
SHANGHAI/SUZHOU, China, April 19 (Reuters) - China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology ...
Johns Hopkins University, home to considerable expertise in RNA sciences and therapeutic development, has announced a new academic collaboration with TriLink BioTechnologies, part of Maravai ...
DURING THE covid-19 pandemic new vaccines were rolled out with unprecedented speed. The fastest to arrive were jabs built from molecules of messenger RNA (mRNA) designed to teach the body how to fight ...
In his new book, “The Catalyst,” Dr. Thomas Cech describes how mRNA in the COVID vaccines encodes the virus’s spike protein. The following is an excerpt from The Catalyst: RNA and the Quest to Unlock ...
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA ...
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies ...
< Photo 1. (From left) Professor Won Do Heo and Jihwan Yu, a Ph.D. Candidate of the Department of Biological Sciences > CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback